IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12018032 B1

PDFFull Text
Date of Patent:
Jun. 25, 2024

Filed:

Aug. 10, 2022

Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-mll interaction

Applicant:

Biomea Fusion, Inc., Redwood City, CA (US);

Inventors:

Priyanka Somanath, Dublin, CA (US);

Daniel Lu, San Jose, CA (US);

Taisei Kinoshita, San Jose, CA (US);

Brian Law, San Jose, CA (US);

Thomas Butler, Redwood City, CA (US);

James T. Palmer, Warrandyte, AU;

Nan-Horng Lin, Vernon Hills, IL (US);

Heow Meng Tan, Cupertino, CA (US);

Angelina Sau Man Wong, Redwood City, CA (US);

Siyi Jiang, Shanghai, CN;

Hongyan He, Shanghai, CN;

Assignee:

BIOMEA FUSION, INC., Redwood City, CA (US);

Attorney:

Squire Patton Boggs (US) LLP

Primary Examiner:

Douglas M Willis

Int. Cl.
CPC ...
A61K 31/4427 (2006.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07D 401/14 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 9/0053 (2013.01); A61K 9/4825 (2013.01); A61K 9/485 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07B 2200/13 (2013.01);
Abstract

Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (I) including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include compound (I), as well as methods of using compound (I), alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Find Patent Forward Citations

Loading…